OTCMKTS:CLPBY - Coloplast A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 6
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$14.89
▲ +0.13 (0.88%)
1 month | 3 months | 12 months
Get New Coloplast A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLPBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLPBY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Coloplast A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $14.89.
Hold
The current consensus among 6 investment analysts is to hold stock in Coloplast A/S. This rating has held steady since February 2020, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
1/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetDetails
1/20/2021Berenberg BankUpgradeSell ➝ Hold
i
1/13/2021BarclaysReiterated RatingUnderweight
i
12/9/2020Morgan StanleyReiterated RatingEqual Weight
i
11/6/2020Morgan StanleyReiterated RatingEqual Weight
i
11/4/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
10/16/2020Berenberg BankReiterated RatingSell
i
9/23/2020BarclaysDowngradeEqual Weight ➝ Underweight
i
9/23/2020Jefferies Financial GroupUpgradeHold ➝ Buy
i
8/19/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
8/19/2020Morgan StanleyReiterated RatingEqual Weight
i
8/11/2020Nordea Equity ResearchDowngradeHold ➝ Sell
i
4/27/2020BarclaysReiterated RatingEqual Weight
i
4/20/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
3/18/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
7/19/2019BarclaysDowngradeOverweight ➝ Equal Weight
i
(Data available from 1/24/2016 forward)
Coloplast A/S logo
Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Read More

Today's Range

Now: $14.89
$14.79
$14.98

50 Day Range

MA: $15.07
$14.50
$15.56

52 Week Range

Now: $14.89
$14.30
$17.80

Volume

84,026 shs

Average Volume

124,463 shs

Market Capitalization

$32.16 billion

P/E Ratio

53.18

Dividend Yield

1.47%

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Coloplast A/S?

The following Wall Street sell-side analysts have issued stock ratings on Coloplast A/S in the last twelve months: Barclays PLC, Berenberg Bank, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Nordea Equity Research, and Zacks Investment Research.

What is the current price target for Coloplast A/S?

0 Wall Street analysts have set twelve-month price targets for Coloplast A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Coloplast A/S in the next year.

What is the current consensus analyst rating for Coloplast A/S?

Coloplast A/S currently has 2 sell ratings, 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CLPBY, but not buy more shares or sell existing shares.

What other companies compete with Coloplast A/S?

How do I contact Coloplast A/S's investor relations team?

Coloplast A/S's physical mailing address is HOLTEDAM 1-3, HUMLEBAEK G7, 3050. The company's listed phone number is 45-4911-1111 and its investor relations email address is [email protected] The official website for Coloplast A/S is www.coloplast.com.